2Mes·

$MEDP (+0,22%) Reports Q3 2024

Sales: 533M vs 541M expected (Miss)

EBIT: 112M vs 101M expected (Beat)

Income: 96M vs 90M expected (Beat)


  • New Business Awards 533M (Miss) leads to Book-To-Bill of 1.00 down from 1.2-1.3 Range YoY


Outlook for FY24:

Rev: 2.11B vs 2.14B expected (Miss)

EBITDA: 460M vs 450M expected (Beat)

Income: 381M vs 371M expected (Beat)


Expectations were apparently very high. The company is more profitable than expected with less growth. Book-To-Bill is approaching 1. A value below 1 signals a shrinking business, but the backlog is almost 3B, which makes MEDP booked out for a year. So there is still enough time to generate new growth

9
25 Commenti

immagine del profilo
a big fall
immediately moves to my watchlist 😅
how do you see medpace now?
1
Visualizza tutti 23 ulteriori risposte
immagine del profilo
The last earnings were already below expectations here.
I think some competitors have also joined the market, which should put pressure on margins.
Partecipa alla conversazione